Developer docs
API playgroundTry for free, no card

Search company profiles

EuBiologics

Full company profile

uuid000n8qg

Namestring
EuBiologics
Legal namestring
EuBiologics Co., Ltd.
Websiteurl
eubiologics.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

EuBiologics Co., Ltd. (KOSDAQ: 206650) is a South Korea-based biopharmaceutical company founded in March 2010 that develops, manufactures, and commercializes vaccines targeting infectious diseases prevalent in low- and middle-income countries, with a strategic pipeline expansion into higher-value indications. The company's core commercial franchise is its WHO-prequalified oral cholera vaccine (OCV) family — Euvichol (2015), Euvichol-Plus (2017), and Euvichol-S (2024) — which are supplied primarily through long-term UNICEF procurement agreements to global cholera-endemic regions. The underlying technology platform is built around three proprietary assets: EcML, a TLR4 agonist adjuvant produced from genetically modified E. coli with ≥90% hexa-acylated purity (licensed from KIST in 2017); rCRM197, a recombinant carrier protein with 10x higher yield than natural CRM197 used in conjugate vaccines; and the SNAP/CoPoP liposome nanoparticle platform accessed via the US joint venture EUPOP Life Sciences with POP Biotechnologies.

The business model operates through four revenue streams: (1) commercial vaccine product sales (Euvichol family plus EuCorVac-19 COVID-19 vaccine) supplied through UNICEF/WHO procurement channels at affordable prices for low-income countries; (2) CRMO (Contract R&D and Manufacturing Organization) services spanning cell line development through commercial GMP production; (3) technology transfer and licensing agreements with regional manufacturers (e.g., Biovac for pentavalent meningococcal conjugate vaccine in South Africa); and (4) adjuvant (EcML) and carrier protein (rCRM197) sales to vaccine developers and research institutions at unit pricing ($200/mg and $260,000/mg respectively). Manufacturing is conducted at two EU-GMP/cGMP-compliant plants in Chuncheon (C Plant and V Plant), with a third plant ($76.8M / 111.5 billion won investment) approved in February 2026 for completion through 2028 to support pipeline products (typhoid, meningococcal, RSV, Herpes Zoster, Alzheimer's). Customers are concentrated among international public health organizations (UNICEF, WHO, GAVI), Korean government health agencies (KDCA), and biopharmaceutical companies requiring CRMO services.

Leadership is split between Co-CEOs Yeong-Ok Baik (Production/Quality/R&D) and Tae-Young Heo (Management Administration), supported by two Vice Presidents heading Production and R&D. The company reported 2024 revenue of 149 billion KRW (~$106M USD), up 76.8% year-over-year, and operating profit of 60.7 billion KRW (~$43M USD), up 55.4% year-over-year. Geographically, EuBiologics operates a Boston-area R&D subsidiary (EUPOP Life Sciences, JV with POP Biotechnologies, established 2020) and serves markets across East Asia, Southeast Asia, South Asia, Africa, the Caribbean, and the EAEU region (the latter enabled by December 2024 EAEU GMP certification).

Short descriptiontext

EuBiologics is a South Korean biopharmaceutical company (KOSDAQ: 206650) that develops, manufactures, and supplies WHO-prequalified oral cholera vaccines to UNICEF and global health agencies, with a pipeline spanning conjugate, RSV, shingles, and Alzheimer's vaccines built on proprietary EcML adjuvant and rCRM197 carrier protein platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine development, oral cholera vaccines, vaccine adjuvants, conjugate vaccines, contract biomanufacturing
Industry4 codes
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Vaccines
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Vaccine Product Sales
TypeOne Time License
Description

Sale of WHO-prequalified oral cholera vaccines (Euvichol, Euvichol-Plus, Euvichol-S) and pipeline vaccines to international organizations and governments. Revenue includes product supply contracts with UNICEF and other global health agencies.

koreaherald.com
2CRMO Services
TypeProfessional Services
Description

Contract Research and Manufacturing Organization services providing cell line development, process development, GMP manufacturing, and regulatory support for biomedicines from early clinical to commercial production stages.

eubiologics.com
3Technology Transfer and Licensing
TypeLicensing Royalties
Description

Revenue from technology transfer agreements for proprietary technologies (EcML, CRM197) and vaccine candidates (meningococcal vaccines, typhoid vaccines) to international partners including Biovac and other regional manufacturers.

4Adjuvant and Carrier Protein Sales
TypeOne Time License
Description

Sale of EcML™ and rCRM197™ as research and commercial-grade immune enhancers and carrier proteins to vaccine developers.

eubiologics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details2 tiers
1EcML™ adjuvant - research and commercial grade
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$200/mg; licensing available; GMP grade available; minimum purchase 5mg

eubiologics.com
2rCRM197™ carrier protein
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$260,000/mg (₩260,000/mg on Korean site); research purpose and GMP grade for vaccine development; custom packaging available

eubiologics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Euvichol
Description

Oral cholera vaccine (OCV) - flagship product

eubiologics.com
+8 more records
Core offering1 text field

EuBiologics develops, manufactures, and supplies vaccines — primarily WHO-prequalified oral cholera vaccines (Euvichol, Euvichol-Plus, Euvichol-S) and a COVID-19 vaccine (EuCorVac-19). The company also sells proprietary immune-enhancing adjuvants (EcML platform) and recombinant carrier proteins (rCRM197), licenses technology, and offers CRMO contract R&D and GMP manufacturing services to biopharmaceutical clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 40% production increase in Euvichol-S compared to Euvichol-Plus through improved antigen composition and manufacturing process
+2 more records
Product overview1 text field

EuBiologics is a Korean biotech company specializing in vaccine development and manufacturing. The company's product portfolio centers on three core areas: (1) Commercial Vaccines: Three oral cholera vaccines (Euvichol®, Euvichol®-Plus, Euvichol®-S) and one COVID-19 vaccine (EuCorVac-19™); (2) Immunostimulants/Adjuvants: EcML™ platform including liposome formulations (ELS, ECLS) and combinations with Alum and QS-21; (3) Carrier Proteins: rCRM197™ for conjugate vaccines. Pipeline includes 9 vaccines in development (Typhoid, Meningococcal quadrivalent/pentavalent, Pneumococcal, RSV, Herpes Zoster, HPV, Alzheimer's, COVID-19). Key platform technologies include EuIMT™ (immune modulation) and EuVCT™ (vaccine conjugation). The company also offers CRMO contract manufacturing services from research through commercial production.

Product and service6 records
1Euvichol®
CategoryOral Cholera Vaccine
Description

Inactivated oral cholera vaccine (OCV) containing V. cholerae O1 and O139 serogroup strains; administered orally twice at two-week intervals. Targets cholera prevention in low and middle-income countries through UNICEF and government procurement.

2Euvichol®-Plus
CategoryOral Cholera Vaccine
Description

Plastic tube formulation of inactivated oral cholera vaccine with easier storage and transport than Euvichol; administered orally twice at two-week intervals.

3Euvichol®-S
CategoryOral Cholera Vaccine
Description

Improved oral cholera vaccine with approximately 40% higher production yield compared to Euvichol-Plus through optimized antigen composition and manufacturing process; same oral administration.

4EuCorVac-19™
CategoryCOVID-19 Vaccine
Description

COVID-19 subunit (recombinant protein) vaccine targeting the RBD of SARS-CoV-2 spike protein, combined with EcML™ adjuvant and CoPoP liposome technology; refrigerated storage; two intramuscular doses four weeks apart.

5EcML™
CategoryVaccine Adjuvant
Description

Monophosphoryl Lipid A (MPLA) adjuvant produced directly from genetically modified E. coli with ≥90% hexa-acylation purity; TLR4 agonist that activates antigen-presenting cells; research and GMP grade available.

6EcML™+Alum
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1LG Chem
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-04-17
Description

Quality by design (QbD) collaboration to strengthen vaccine quality systems and manufacturing capabilities. Initial focus on improving production quality for LG Chem's acellular pertussis vaccine clinical trial materials. Supports EuBiologics' expansion into high-value vaccines and advanced global markets.

koreaherald.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Partnership to develop nanoparticle-based Nipah virus vaccine candidate with broad-coverage to address pandemic potential. Development scheduled from April 2025 to December 2026. Leverages SNAP platform and EuIMT technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

US-based joint venture company established October 2020 (EUPOP Life Sciences) advancing vaccine development including SNAP nanoparticle platform targeting avian flu (H5N1), RSV, shingles, and Alzheimer's disease. POP Biotechnologies brings SNAP technology; EuBiologics provides EuIMT and manufacturing capabilities.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2023-09-01
Description

Technology transfer partnership with South African biopharmaceutical company Biovac to establish local production of pentavalent meningococcal conjugate vaccine targeting the African meningitis belt. Part of regional capacity building for vaccine self-sufficiency.

5Genofocus
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2019-05-01
Description

Joint development partnership for rCRM197 carrier protein technology. Contributed to 10x yield improvement in recombinant CRM197 production.

eubiologics.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-11-01
Description

Technology licensing agreement for EcML (monophosphoryl lipid A) immune enhancement technology. Licensed on November 13, 2017. Core platform technology for vaccine adjuvant development.

7International Vaccine Institute (IVI)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2010-09-01
Description

Original technology transfer agreement for oral cholera vaccine (OCV) development. Foundation for company's first WHO PQ product. Long-standing relationship supporting global public health mission.

eubiologics.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korean vaccine and plasma product manufacturer. A domestic peer with overlapping vaccine portfolio (influenza, hepatitis, DTaP combination vaccines) and similar KOSDAQ/KOSPI-listed status and global public health focus.

TypeDirect peer
Description

Indian vaccine manufacturer and a direct competitor in the WHO-prequalified oral cholera vaccine market (Hillchol). Competes head-to-head with EuBiologics for UNICEF/Gavi OCV tenders and shares the focus on affordable vaccines for LMICs.

3Shantha Biotechnics (Sanofi)
TypeDirect peer
Description

Sanofi-owned Indian vaccine maker of Shanchol, the historical OCV market leader and a primary UNICEF supplier. Competes directly with EuBiologics' Euvichol franchise in global cholera tenders.

4Biological E
TypeDirect peer
Description

Indian vaccine and biologics manufacturer with WHO-prequalified products and a similar focus on affordable conjugate and pediatric vaccines for LMIC markets. Comparable scale, customer base (UNICEF, Gavi), and product breadth.

TypeDirect peer
Description

Korean vaccine company developing and manufacturing vaccines (COVID-19, influenza, pneumococcal, typhoid). Comparable Korean-based vaccine development platform with WHO PQ ambitions and overlapping pipeline in RSV/typhoid.

TypeDirect peer
Description

World's largest vaccine manufacturer by doses and the dominant UNICEF supplier. Competes with EuBiologics across conjugate vaccine categories (meningococcal, pneumococcal) and on price-driven LMIC procurement.

7LG Chem (Life Sciences)
TypeRegional player
Description

Korean chemical/pharma conglomerate with a Life Sciences division and vaccine assets (acellular pertussis). Recently partnered with EuBiologics on QbD manufacturing; a domestic competitor for Korean vaccine R&D talent and government contracts.

8Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccines division of Sanofi and the parent of Shantha. Operates broadly across influenza, pediatric, travel, and emerging disease vaccines and competes with EuBiologics wherever its portfolio overlaps (especially via Shantha in OCV).

TypeBroad incumbent
Description

Global vaccines leader (Shingrix, Arexvy, Bexsero, Cervarix). Competes with EuBiologics' pipeline targets — particularly the Herpes Zoster, RSV, and HPV programs — and sets the efficacy/regulatory benchmark.

TypeEmerging player
Description

Singapore-based vaccine R&D organization focused on affordable vaccines for LMICs (cholera, shigella, rotavirus). Mission-aligned peer with overlapping global health focus and emerging-pipeline approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EuBiologics

Biopharmaceutical Vaccineseubiologics.com

EuBiologics is a South Korean biopharmaceutical company (KOSDAQ: 206650) that develops, manufactures, and supplies WHO-prequalified oral cholera vaccines to UNICEF and global health agencies, with a pipeline spanning conjugate, RSV, shingles, and Alzheimer's vaccines built on proprietary EcML adjuvant and rCRM197 carrier protein platforms.

What EuBiologics does

EuBiologics Co., Ltd. (KOSDAQ: 206650) is a South Korea-based biopharmaceutical company founded in March 2010 that develops, manufactures, and commercializes vaccines targeting infectious diseases prevalent in low- and middle-income countries, with a strategic pipeline expansion into higher-value indications. The company's core commercial franchise is its WHO-prequalified oral cholera vaccine (OCV) family — Euvichol (2015), Euvichol-Plus (2017), and Euvichol-S (2024) — which are supplied primarily through long-term UNICEF procurement agreements to global cholera-endemic regions. The underlying technology platform is built around three proprietary assets: EcML, a TLR4 agonist adjuvant produced from genetically modified E. coli with ≥90% hexa-acylated purity (licensed from KIST in 2017); rCRM197, a recombinant carrier protein with 10x higher yield than natural CRM197 used in conjugate vaccines; and the SNAP/CoPoP liposome nanoparticle platform accessed via the US joint venture EUPOP Life Sciences with POP Biotechnologies.

The business model operates through four revenue streams: (1) commercial vaccine product sales (Euvichol family plus EuCorVac-19 COVID-19 vaccine) supplied through UNICEF/WHO procurement channels at affordable prices for low-income countries; (2) CRMO (Contract R&D and Manufacturing Organization) services spanning cell line development through commercial GMP production; (3) technology transfer and licensing agreements with regional manufacturers (e.g., Biovac for pentavalent meningococcal conjugate vaccine in South Africa); and (4) adjuvant (EcML) and carrier protein (rCRM197) sales to vaccine developers and research institutions at unit pricing ($200/mg and $260,000/mg respectively). Manufacturing is conducted at two EU-GMP/cGMP-compliant plants in Chuncheon (C Plant and V Plant), with a third plant ($76.8M / 111.5 billion won investment) approved in February 2026 for completion through 2028 to support pipeline products (typhoid, meningococcal, RSV, Herpes Zoster, Alzheimer's). Customers are concentrated among international public health organizations (UNICEF, WHO, GAVI), Korean government health agencies (KDCA), and biopharmaceutical companies requiring CRMO services.

Leadership is split between Co-CEOs Yeong-Ok Baik (Production/Quality/R&D) and Tae-Young Heo (Management Administration), supported by two Vice Presidents heading Production and R&D. The company reported 2024 revenue of 149 billion KRW (~$106M USD), up 76.8% year-over-year, and operating profit of 60.7 billion KRW (~$43M USD), up 55.4% year-over-year. Geographically, EuBiologics operates a Boston-area R&D subsidiary (EUPOP Life Sciences, JV with POP Biotechnologies, established 2020) and serves markets across East Asia, Southeast Asia, South Asia, Africa, the Caribbean, and the EAEU region (the latter enabled by December 2024 EAEU GMP certification).

EuBiologics firmographics

Firmographics
Name
EuBiologics
Legal name
EuBiologics Co., Ltd.
Website
https://eubiologics.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
EuBiologics is a South Korean biopharmaceutical company (KOSDAQ: 206650) that develops, manufactures, and supplies WHO-prequalified oral cholera vaccines to UNICEF and global health agencies, with a pipeline spanning conjugate, RSV, shingles, and Alzheimer's vaccines built on proprietary EcML adjuvant and rCRM197 carrier protein platforms.
Ownership category
akta.pro rank

EuBiologics industry classification

Industry
Product category
Biopharmaceutical Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Vaccine development
  • Oral cholera vaccines
  • Vaccine adjuvants
  • Conjugate vaccines
  • Contract biomanufacturing

Where EuBiologics is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices5 records

Markets served

EuBiologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Vaccine Product Sales: Sale of WHO-prequalified oral cholera vaccines (Euvichol, Euvichol-Plus, Euvichol-S) and pipeline vaccines to international organizations and governments. Revenue includes product supply contracts with UNICEF and other global health agencies.
  2. CRMO Services: Contract Research and Manufacturing Organization services providing cell line development, process development, GMP manufacturing, and regulatory support for biomedicines from early clinical to commercial production stages.
  3. Technology Transfer and Licensing: Revenue from technology transfer agreements for proprietary technologies (EcML, CRM197) and vaccine candidates (meningococcal vaccines, typhoid vaccines) to international partners including Biovac and other regional manufacturers.
  4. Adjuvant and Carrier Protein Sales: Sale of EcML™ and rCRM197™ as research and commercial-grade immune enhancers and carrier proteins to vaccine developers.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goEcML™ adjuvant - research and commercial grade
Unit PricingPay-as-you-gorCRM197™ carrier protein

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

EuBiologics product offering

Product offering

Core offering

EuBiologics develops, manufactures, and supplies vaccines — primarily WHO-prequalified oral cholera vaccines (Euvichol, Euvichol-Plus, Euvichol-S) and a COVID-19 vaccine (EuCorVac-19). The company also sells proprietary immune-enhancing adjuvants (EcML platform) and recombinant carrier proteins (rCRM197), licenses technology, and offers CRMO contract R&D and GMP manufacturing services to biopharmaceutical clients.

Product overview

EuBiologics is a Korean biotech company specializing in vaccine development and manufacturing. The company's product portfolio centers on three core areas: (1) Commercial Vaccines: Three oral cholera vaccines (Euvichol®, Euvichol®-Plus, Euvichol®-S) and one COVID-19 vaccine (EuCorVac-19™); (2) Immunostimulants/Adjuvants: EcML™ platform including liposome formulations (ELS, ECLS) and combinations with Alum and QS-21; (3) Carrier Proteins: rCRM197™ for conjugate vaccines. Pipeline includes 9 vaccines in development (Typhoid, Meningococcal quadrivalent/pentavalent, Pneumococcal, RSV, Herpes Zoster, HPV, Alzheimer's, COVID-19). Key platform technologies include EuIMT™ (immune modulation) and EuVCT™ (vaccine conjugation). The company also offers CRMO contract manufacturing services from research through commercial production.

Differentiator

Problem solved

Functional benefit

Brands

  • Euvichol: Oral cholera vaccine (OCV) - flagship product
  • Euvichol-Plus
  • Euvichol-S
  • EuCorVac-19
  • EuRSV
  • EuHZV
  • EcML
  • rCRM197
  • CRMO

Products and services

  • Euvichol® Inactivated oral cholera vaccine (OCV) containing V. cholerae O1 and O139 serogroup strains; administered orally twice at two-week intervals. Targets cholera prevention in low and middle-income countries through UNICEF and government procurement.
  • Euvichol®-Plus Plastic tube formulation of inactivated oral cholera vaccine with easier storage and transport than Euvichol; administered orally twice at two-week intervals.
  • Euvichol®-S Improved oral cholera vaccine with approximately 40% higher production yield compared to Euvichol-Plus through optimized antigen composition and manufacturing process; same oral administration.
  • EuCorVac-19™ COVID-19 subunit (recombinant protein) vaccine targeting the RBD of SARS-CoV-2 spike protein, combined with EcML™ adjuvant and CoPoP liposome technology; refrigerated storage; two intramuscular doses four weeks apart.
  • EcML™ Monophosphoryl Lipid A (MPLA) adjuvant produced directly from genetically modified E. coli with ≥90% hexa-acylation purity; TLR4 agonist that activates antigen-presenting cells; research and GMP grade available.
  • EcML™+Alum

Quantifiable outcome

  • 40% production increase in Euvichol-S compared to Euvichol-Plus through improved antigen composition and manufacturing process
  • +2 more outcomes

Companies that use EuBiologics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

EuBiologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EuBiologics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered strategic, core and supporting.

  • LG ChemstrategicStrategic or Co-development Partner · 17 April 2026Quality by design (QbD) collaboration to strengthen vaccine quality systems and manufacturing capabilities. Initial focus on improving production quality for LG Chem's acellular pertussis vaccine clinical trial materials. Supports EuBiologics' expansion into high-value vaccines and advanced global markets.
  • Korea Disease Control and Prevention Agency (KDCA)coreStrategic or Co-development Partner · 5 March 2026Partnership to develop nanoparticle-based Nipah virus vaccine candidate with broad-coverage to address pandemic potential. Development scheduled from April 2025 to December 2026. Leverages SNAP platform and EuIMT technology.
  • POP Biotechnologies / EUPOP Life SciencescoreStrategic or Co-development Partner · 1 June 2025US-based joint venture company established October 2020 (EUPOP Life Sciences) advancing vaccine development including SNAP nanoparticle platform targeting avian flu (H5N1), RSV, shingles, and Alzheimer's disease. POP Biotechnologies brings SNAP technology; EuBiologics provides EuIMT and manufacturing capabilities.
  • BiovacstrategicTechnology or Integration · 1 September 2023Technology transfer partnership with South African biopharmaceutical company Biovac to establish local production of pentavalent meningococcal conjugate vaccine targeting the African meningitis belt. Part of regional capacity building for vaccine self-sufficiency.
  • GenofocussupportingTechnology or Integration · 1 May 2019Joint development partnership for rCRM197 carrier protein technology. Contributed to 10x yield improvement in recombinant CRM197 production.
  • Korea Institute of Science and Technology (KIST)coreTechnology or Integration · 1 November 2017Technology licensing agreement for EcML (monophosphoryl lipid A) immune enhancement technology. Licensed on November 13, 2017. Core platform technology for vaccine adjuvant development.
  • International Vaccine Institute (IVI)coreTechnology or Integration · 1 September 2010Original technology transfer agreement for oral cholera vaccine (OCV) development. Foundation for company's first WHO PQ product. Long-standing relationship supporting global public health mission.

Scale indicators6 records

Recent moves9 records

Expansion highlights4 records

EuBiologics competitors and assessment

Company assessment

Direct peers

  • GC Biopharma (formerly Green Cross): Korean vaccine and plasma product manufacturer. A domestic peer with overlapping vaccine portfolio (influenza, hepatitis, DTaP combination vaccines) and similar KOSDAQ/KOSPI-listed status and global public health focus.
  • Bharat Biotech: Indian vaccine manufacturer and a direct competitor in the WHO-prequalified oral cholera vaccine market (Hillchol). Competes head-to-head with EuBiologics for UNICEF/Gavi OCV tenders and shares the focus on affordable vaccines for LMICs.
  • Shantha Biotechnics (Sanofi): Sanofi-owned Indian vaccine maker of Shanchol, the historical OCV market leader and a primary UNICEF supplier. Competes directly with EuBiologics' Euvichol franchise in global cholera tenders.
  • Biological E: Indian vaccine and biologics manufacturer with WHO-prequalified products and a similar focus on affordable conjugate and pediatric vaccines for LMIC markets. Comparable scale, customer base (UNICEF, Gavi), and product breadth.
  • SK Bioscience: Korean vaccine company developing and manufacturing vaccines (COVID-19, influenza, pneumococcal, typhoid). Comparable Korean-based vaccine development platform with WHO PQ ambitions and overlapping pipeline in RSV/typhoid.
  • Serum Institute of India: World's largest vaccine manufacturer by doses and the dominant UNICEF supplier. Competes with EuBiologics across conjugate vaccine categories (meningococcal, pneumococcal) and on price-driven LMIC procurement.

Regional players

  • LG Chem (Life Sciences): Korean chemical/pharma conglomerate with a Life Sciences division and vaccine assets (acellular pertussis). Recently partnered with EuBiologics on QbD manufacturing; a domestic competitor for Korean vaccine R&D talent and government contracts.

Broad incumbents

  • Sanofi Pasteur: Global vaccines division of Sanofi and the parent of Shantha. Operates broadly across influenza, pediatric, travel, and emerging disease vaccines and competes with EuBiologics wherever its portfolio overlaps (especially via Shantha in OCV).
  • GSK: Global vaccines leader (Shingrix, Arexvy, Bexsero, Cervarix). Competes with EuBiologics' pipeline targets — particularly the Herpes Zoster, RSV, and HPV programs — and sets the efficacy/regulatory benchmark.

Emerging players

  • Hilleman Laboratories: Singapore-based vaccine R&D organization focused on affordable vaccines for LMICs (cholera, shigella, rotavirus). Mission-aligned peer with overlapping global health focus and emerging-pipeline approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

EuBiologics social profiles

Digital presence

EuBiologics compliance and trust

Trust signal

Compliance8 records

EuBiologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EuBiologics leadership team

Management profile

Number of profiles

Profiles4 records

EuBiologics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

EuBiologics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EuBiologics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EuBiologics

What does EuBiologics do?

EuBiologics develops, manufactures, and supplies vaccines — primarily WHO-prequalified oral cholera vaccines (Euvichol, Euvichol-Plus, Euvichol-S) and a COVID-19 vaccine (EuCorVac-19). The company also sells proprietary immune-enhancing adjuvants (EcML platform) and recombinant carrier proteins (rCRM197), licenses technology, and offers CRMO contract R&D and GMP manufacturing services to biopharmaceutical clients.

Is EuBiologics a public or private company?

EuBiologics is a public company. It is classified as public and is currently operating.

When was EuBiologics founded?

EuBiologics was founded in 2010. It employs 11 to 50 people.

Where is EuBiologics based?

EuBiologics is headquartered in Seoul, South Korea, in the Asia region.

How does EuBiologics make money?

Four revenue lines are on record. Vaccine Product Sales are the primary driver. The others are CRMO Services, technology Transfer and Licensing and adjuvant and Carrier Protein Sales.

Who are EuBiologics's main competitors?

Direct peers on record are GC Biopharma (formerly Green Cross), Bharat Biotech, Shantha Biotechnics (Sanofi), Biological E, SK Bioscience and Serum Institute of India. LG Chem (Life Sciences) is listed as a regional player. Broad incumbents are Sanofi Pasteur and GSK. Hilleman Laboratories is listed as an emerging player.

Does EuBiologics have an API?

No public API is recorded for EuBiologics.

What industry is EuBiologics in?

EuBiologics's product category is Biopharmaceutical Vaccines. Its primary akta.pro industry code is HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens), with a secondary code of HLAIAEAE, Travel & Tropical Disease Vaccines. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NaverHow EuBiologics' Cholera Vaccine is Driving Profits: Insights for InvestorsEuBiologics plans to boost profits in H2 by shipping its 51.6B KRW cholera vaccine contract, projecting 135B KRW sales and 45B KRW operating profit. The company is also advancing shingles and Alzheimer's vaccines, with shingles vaccine IND submitted for Phase 2 trials.The Korea HeraldBeyond WHO approval, EuBiologics targets global typhoid vaccine marketEuBiologics' typhoid conjugate vaccine EuTYPH-C received WHO prequalification in August, becoming the first vaccine backed by the RIGHT Foundation to clear that bar. The company plans to target an initial UNICEF allocation of 4-5 million doses in the second half of next year, with talks expected to reopen before year's end.NaverBeyond WHO approval, EuBiologics targets global typhoid vaccine marketEuBiologics' typhoid conjugate vaccine EuTYPH-C received WHO prequalification in August, becoming the first vaccine backed by the RIGHT Foundation to clear the bar. The company plans to target an initial UNICEF allocation of 4-5 million doses in the second half of next year, after a late tender bid was unsuccessful. It also plans a single-dose vial version and a combination cholera-typhoid vaccine.The Korea HeraldEuBiologics secures WHO prequalification for typhoid vaccineEuBiologics received World Health Organization prequalification for its typhoid conjugate vaccine, enabling the company to bid for international public procurement programs. This certification follows a successful clinical trial in Kenya and Senegal and marks the first time Korea’s Ministry of Food and Drug Safety inspection was recognized by the WHO. The company plans to resume discussions with UNICEF to supply the vaccine through global health initiatives.DevdiscourseGlobal Markets Struggle Amid Inflation Fears and Rising Bond YieldsThe African Development Bank Group has finalized a loan of up to $15 million for South African vaccine maker Biovac to build a multi-vaccine manufacturing facility in Cape Town, expected to lift Biovac's annual capacity to 500 million doses by 2028. The facility will initially produce oral cholera vaccines, later expanding to include inactivated polio, pneumococcal conjugate, and meningitis vaccines, supported by technology-transfer partnerships with Sanofi, the International Vaccine Institute, Biological E, EuBiologics, and Bharat Biotech. The $1.2 billion Gavi African Vaccine Manufacturing Accelerator will provide milestone payments after WHO prequalification, as part of a broader push to reduce Africa's reliance on imported vaccines, which currently exceed 99 percent of the continent's supply.The Korea HeraldEuBiologics secures FDA registration for EcML vaccine adjuvantEuBiologics has completed registration of its proprietary EcML vaccine adjuvant with the FDA's Drug Master File system, obtaining an official filing number to support future vaccine development and licensing partnerships. The monophosphoryl lipid A-based adjuvant was developed using recombinant technology licensed from the Korea Institute of Science and Technology and is manufactured through EuBiologics' proprietary process. The company is developing several EcML-based vaccine candidates through its US joint venture EUPOP Life Sciences, including vaccines for shingles, respiratory syncytial virus, and Alzheimer's disease.AInvestEubioLogics Co Ltd - wins 10.1 bln won orderEubioLogics Co Ltd has secured an order valued at 10.1 billion won. The article reports this achievement without discussing any broader implications or subsequent developments.KBREuBiologics-backed Pop Bio wins $9.7 mil. CEPI funding for avian flu vaccine platformPop Biotechnologies, a U.S. affiliate of Korean vaccine developer EuBiologics, has received up to $9.7 million in additional funding from CEPI to advance its SNAP nanoparticle vaccine platform and an H5N1 avian influenza vaccine candidate into early-stage clinical trials in the United States. The funding, which follows an initial $1.5 million CEPI grant in July last year, is intended to accelerate vaccine development timelines by leveraging SNAP's ability to simplify antigen purification and nanoparticle manufacturing. For EuBiologics, the CEPI funding represents a strategic validation of the SNAP platform, which the company is also combining with its proprietary EuIMT immune-enhancing technology to develop vaccines targeting RSV, shingles, and Alzheimer's disease.openPR.comSegmentation, Major Trends, and Competitive Overview of the Meningococcal Disease Vaccine MarketThe Business Research Company released a market report projecting the global meningococcal disease vaccine market to reach $4.11 billion by 2030, growing at a 9.6% CAGR, driven by international travel, preventive healthcare emphasis, and expanded immunization programs. In September 2023, South African biopharmaceutical company Biovac partnered with South Korea-based EuBiologics Co. Ltd to transfer technology and establish local production of a pentavalent meningococcal conjugate vaccine targeting the African meningitis belt. In March 2024, Indian manufacturer Hindustan Syringes and Medical Devices launched the Dispojekt single-use safety syringe with SIP Shield technology, investing Rs 70 crore to scale production to 300 million units annually.The Korea HeraldEuBiologics teams up with LG Chem to strengthen vaccine quality for global pushEuBiologics has signed a memorandum of understanding with LG Chem to strengthen quality systems and manufacturing capabilities across its vaccine research, development, and production operations. The partnership will focus on quality by design elements including process design, quality risk management, and design space establishment, with EuBiologics initially improving production quality for LG Chem's acellular pertussis vaccine clinical trial materials. The collaboration supports EuBiologics' strategic expansion beyond public health vaccines into high-value vaccines and advanced global markets.